TECHNOLOGY APPRAISAL IN ACTION Mrs Karen Samuels Programme Manager
WHO WHAT WHERE RELATED ORGANISATIONS CHALLENGES FUTURE
WMP MULTIDISCIPLINARY PARTNERSHIP 1. WMIC 2. WeMeReC 3. WCM Therapeutics and Toxicology Centre 4. YCC Wales (Core WMP)
ESTABLISHED 2002 Appraised up to 8 High cost drugs per year Strategic advice Met 4 times per year
ORGANISATIONAL STRUCTURE AWMSG NHSIFAWPAG
INITIAL PERIOD ( ) One step process Public meeting WMP appraisal team One medical expert Patient perspective Two pharmaceutical company representatives
CHALLENGES One step Public nature Medical expert PIG submission Health Economic issues
CHALLENGES (continued) Small number of specialist medicines Dependent on pharmaceutical Industry submission Service links Need Commissioners (HCW) Public demand e.g. trastusumab
APRIL 2007 Second phase, 32 appraisals per year 1. High cost 2. Cancer drugs 3. Cardiovascular drugs
MODIFIED PROCESS Met with SMC New sub group NMG
PROCESS In the pipeline MHRA licence (MA) Company launch in the UK Preliminary application (Form A) Detailed application (Form B) Patient Interest Groups
NMG ROLE AND MEMBERSHIP Expert clinical & cost effectiveness advice to AWMSG Broad spectrum membership Lay representative ABPI representative Not in public
DATA CONSIDERED WMP assessment report (AS AR) Company response Company’s detailed application (Form B) Advice from Medical Expert (s) Patient interest group submission
AWMSG ROLE AND MEMBERSHIP Consider strategic, societal, affordability aspects Broader strategic Senior NHS managers Senior Finance directors Lay representative ABPI representative
DATA CONSIDERED NMG preliminary appraisal report (PAR) Company response to the PAR Patient Interest Group submissions
HOW? In public Announced at the meeting Minister for Health and Social Services
RELATED ORGANISATIONS NICE/AWMSG/SMC ABPI CDG All-Wales Cardiac and Cancer networks Health Commission Wales
REQUEST FOR APPRAISAL OF CANCER DRUGS Is drug/indication licensed? Is drug being Appraised by NICE? Await NICE guidance Refer to AWMSG for appraisal Refer to Cancer New Drugs Group for appraisal Yes No
ALL WALES CANCER DRUGS GROUP No backlog AWCDG to help prioritise Engaging network –Oncologists –Oncology pharmacists Horizon scanning
England and Wales - NICE takes precedence Wales - AWMSG Local MTC’s
SCOTLAND SMC Streamlined process Similar paperwork Simultaneous submissions
ABPI Users Group Regular Input process
FUTURE Extend to all new medicines? Increased links with patient groups Further collaboration with NICE/SMC Review process after 2 cycles